Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
Lisa E. Gralinski(University of North Carolina at Chapel Hill), John M. Dye(United States Army Medical Research Institute of Infectious Diseases), Chengzi I. Kaku(Scripps Institution of Oceanography), Bronwyn M. Gunn(Washington State University), Ralph S. Baric(University of North Carolina at Chapel Hill), Michael B. Battles(Adimab (United States)), Thomas J. Yockachonis(Washington State University), Jonathan Belk(Adimab (United States)), Daniel Wrapp(Duke University), C. Garrett Rappazzo(Adimab (United States)), Mrunal Sakharkar(Adimab (United States)), Andrew S. Herbert(United States Army Medical Research Institute of Infectious Diseases), Laura M. Deveau(Adimab (United States)), Cecilia M. O apos Brien, Dennis R. Burton(Scripps Research Institute), James E. Voss(Scripps Research Institute), James C. Geoghegan(Adimab (United States)), Linghang Peng(Scripps Research Institute), Deli Huang(Scripps Research Institute), Trevor Scobey(University of North Carolina at Chapel Hill), David Nemazee(Scripps Research Institute), Linlin Yang, Yixuan Hou(University of North Carolina at Chapel Hill), Laura M. Walker, Jason S. McLellan(The University of Texas at Austin), Michael E. Brown, Longping V. Tse(Saint Louis University)
Cited by 0
Related Papers
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
|Science|2020|9.8k
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
|Nature Communications|2020|1.8k
Site-specific glycan analysis of the SARS-CoV-2 spike
|Science|2020|1.7k
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
|Science|2020|1.4k